Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Is there a role for bevacizumab in the treatment of glioblastoma?

Chi AS, Chamberlain MC.

Oncologist. 2013;18(10):1080-2. doi: 10.1634/theoncologist.2013-0296. Epub 2013 Sep 20. No abstract available.

2.

Bevacizumab and recurrent malignant gliomas: a European perspective.

Wick W, Weller M, van den Bent M, Stupp R.

J Clin Oncol. 2010 Apr 20;28(12):e188-9; author reply e190-2. doi: 10.1200/JCO.2009.26.9027. Epub 2010 Feb 16. No abstract available.

PMID:
20159801
3.

Bevacizumab for acute neurologic deterioration in patients with glioblastoma.

Kaley T, Nolan C, Carver A, Omuro A.

CNS Oncol. 2013 Sep;2(5):413-8. doi: 10.2217/cns.13.40.

PMID:
25054664
4.

High-dose antiangiogenic therapy for glioblastoma: less may be more?

de Groot JF.

Clin Cancer Res. 2011 Oct 1;17(19):6109-11. doi: 10.1158/1078-0432.CCR-11-1853. Epub 2011 Aug 18.

5.

Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.

Huang RY, Rahman R, Hamdan A, Kane C, Chen C, Norden AD, Reardon DA, Mukundun S, Wen PY.

Cancer. 2013 Oct 1;119(19):3479-88. doi: 10.1002/cncr.28210. Epub 2013 Jul 2.

6.

Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.

D'Alessandris QG, Montano N, Cenci T, Martini M, Lauretti L, Bianchi F, Larocca LM, Maira G, Fernandez E, Pallini R.

Acta Neurochir (Wien). 2013 Jan;155(1):33-40. doi: 10.1007/s00701-012-1536-5. Epub 2012 Nov 8.

PMID:
23132371
7.

Treatment of glioblastoma with bevacizumab: has a new standard therapy been defined?

Chamberlain MC.

CNS Drugs. 2011 Oct 1;25(10):815-8. doi: 10.2165/11587880-000000000-00000. No abstract available.

PMID:
21936584
8.

Bevacizumab in glioblastoma multiforme.

Specenier P.

Expert Rev Anticancer Ther. 2012 Jan;12(1):9-18. doi: 10.1586/era.11.179. Review.

PMID:
22149428
9.

Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.

Ellingson BM, Sahebjam S, Kim HJ, Pope WB, Harris RJ, Woodworth DC, Lai A, Nghiemphu PL, Mason WP, Cloughesy TF.

AJNR Am J Neuroradiol. 2014 Apr;35(4):673-9. doi: 10.3174/ajnr.A3748. Epub 2013 Oct 17.

10.

Spinal cord metastasis in a patient treated with bevacizumab for glioblastoma.

Lomax AJ, Yannakou CK, Rosenthal MA.

Target Oncol. 2013 Jun;8(2):153-5. doi: 10.1007/s11523-013-0270-0. Epub 2013 Feb 21.

PMID:
23430346
11.

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.

Reardon DA, Herndon JE 2nd, Peters KB, Desjardins A, Coan A, Lou E, Sumrall AL, Turner S, Lipp ES, Sathornsumetee S, Rich JN, Sampson JH, Friedman AH, Boulton ST, Bigner DD, Friedman HS, Vredenburgh JJ.

Br J Cancer. 2012 Oct 23;107(9):1481-7. doi: 10.1038/bjc.2012.415. Epub 2012 Oct 4.

12.

Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?

Desjardins A.

Nat Rev Neurol. 2015 Aug;11(8):429-30. doi: 10.1038/nrneurol.2015.127. Epub 2015 Jul 21. No abstract available.

PMID:
26195258
13.

[An evaluation of fatigue in patients with glioblastoma relapse treated with the combination of irinotecan-bevacizumab].

Dehais C, Souvannavong V, Nguyen BK, Jouniaux-Delbez N, Golmard JL, Tadrist C, Liou A, Delattre JY.

Rev Neurol (Paris). 2011 Nov;167(11):841-6. doi: 10.1016/j.neurol.2011.01.016. Epub 2011 Apr 22. French.

PMID:
21514945
14.

Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.

Narita Y.

Jpn J Clin Oncol. 2013 Jun;43(6):587-95. doi: 10.1093/jjco/hyt051. Epub 2013 Apr 12. Review.

PMID:
23585688
15.

Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma.

Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR, Xue X, Goldin J, Brown MS, Nghiemphu PL, Tran A, Cloughesy TF.

AJNR Am J Neuroradiol. 2011 May;32(5):882-9. doi: 10.3174/ajnr.A2385. Epub 2011 Feb 17.

16.

Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.

Kovic B, Xie F.

J Clin Oncol. 2015 Jul 10;33(20):2296-302. doi: 10.1200/JCO.2014.59.7245. Epub 2015 May 26. Review.

PMID:
26014296
17.

Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.

Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, Kumar SK, Kimlinger TK, Northfelt DW, Flynn PJ, Jaeckle KA, Kaufmann TJ, Buckner JC.

Clin Cancer Res. 2013 Sep 1;19(17):4816-23. doi: 10.1158/1078-0432.CCR-13-0708. Epub 2013 Jul 5.

18.

Bevacizumab alone at 5 mg/kg in an every-3-week schedule for patients with recurrent glioblastomas: a single center experience.

Kaloshi G, Brace G, Rroji A, Bushati T, Roci E, Hoxha M, Fejzo G, Petrela M.

Tumori. 2013 Sep-Oct;99(5):601-3. doi: 10.1700/1377.15309.

PMID:
24362864
19.

Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.

Kilickap S, Oztoprak I, Yucel B.

Acta Oncol. 2012 Apr;51(4):544-6. doi: 10.3109/0284186X.2011.644251. Epub 2011 Dec 27. No abstract available.

PMID:
22201408
20.

First-line bevacizumab for glioblastoma: what do recent Trail results mean for future treatment?

Marosi C.

CNS Oncol. 2013 Nov;2(6):473-4. doi: 10.2217/cns.13.41. No abstract available.

PMID:
25054815

Supplemental Content

Support Center